UVEAL MELANOMA

This early-stage study is testing a new type of cell therapy for people with advanced solid tumors, including melanoma, that have spread and are not responding to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack c…

This is the first study in people testing a new radioactive drug called 225Ac-MTI-201 for uveal melanoma, a rare eye cancer that has spread. The main goal is to find the highest dose that is safe for patients who have already tried at least one other treatment. Researchers will g…

This early-stage study is testing a personalized treatment called lifileucel for patients with advanced uveal melanoma (a rare eye cancer) or certain aggressive soft-tissue sarcomas. Doctors take a patient's own immune cells from their tumor, grow large numbers of them in a lab, …

This study is testing an experimental drug called tebentafusp in people with metastatic uveal melanoma, a rare but aggressive eye cancer that has spread to other parts of the body. The trial will enroll 44 previously untreated patients who have a specific genetic marker (HLA-A*02…

This study is testing whether giving a new drug called darovasertib before standard eye cancer treatments helps preserve patients' vision and prevents the need to remove the eye. It involves 520 people with a specific eye cancer called uveal melanoma that hasn't spread. The goal …

This study is testing a new drug called belzupacap sarotalocan for people with early-stage eye tumors. It aims to see if the drug, which is injected near the eye and activated with a laser, is safe and can stop the tumors from growing better than a sham (fake) procedure. The tria…

This study is testing a combination of two existing drugs, olaparib and pembrolizumab, to see if they can work together to control advanced uveal melanoma, a rare and aggressive cancer that starts in the eye. It will involve about 37 adults whose cancer has spread. The main goal …

This early-stage trial is testing a new cancer drug called NN3201 for the first time in people. The study aims to find a safe dose and see how well the drug works against several advanced solid tumors that have a specific protein called c-Kit. Researchers will enroll 67 adults wi…

This study tests whether a drug called tebentafusp can prevent cancer from returning in people with high-risk eye melanoma after their initial treatment. About 290 patients who have completed treatment for their primary eye tumor will be randomly assigned to either receive the dr…

This study aims to find blood markers that can detect the early spread of uveal melanoma (a type of eye cancer) to the liver. It will follow 700 patients at high risk of relapse, giving them regular MRI scans and blood tests for up to 10 years. The goal is to learn if these marke…

This study aims to better understand the BAP1 hereditary cancer syndrome, which increases risk for several cancers including eye melanoma, skin melanoma, and mesothelioma. Researchers will study 500 participants with personal or family history of these cancers to identify pattern…

This study aims to understand how a specific eye cancer treatment affects patients' quality of life, symptoms, and daily functioning. It involves 15 people who are already enrolled in a related treatment trial. Researchers will collect feedback through online surveys over two yea…

This study aims to understand how the body's immune system responds to a specific liver cancer treatment. It involves 10 adults with eye melanoma that has spread to the liver. Researchers will take small tissue and blood samples before and after the treatment to see how immune ce…